1. Scrip
  2. >>Business
  3. >>Strategy

Dyne Hopes DM1 And DMD Mid-Stage Data Can Lead To Accelerated Approval

 
• By Joseph Haas

Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.

Expediting
Dyne plans to pursue accelerated approved in both DM1 and DMD • Source: Shutterstock

Dyne Therapeutics has reported new data from Phase I/II studies in myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy that it believes can position each candidate for US accelerated approval with best-in-class potential, and analysts see as validating the Waltham, MA-based company’s platform for oligonucleotide therapeutic.

Key Takeaways

  • Dyne reported new data from ongoing Phase I/II trials of its oligonucleotide conjugate therapies in DM1 and DMD that it thinks offer best-in-class potential.

On 20 May, Dyne reported that DYNE-101, its oligonucleotide antibody-drug conjugate (ADC) therapy for DM1, demonstrated dose-dependent mean splicing correction...

More from Strategy

BIO Notebook: IPO Window Stays Shut, PRVs Need To Be A Priority, And Focusing On Gene Therapy Safety

 
• By Mandy Jackson and Sarah Karlin-Smith

Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

More from Business

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.